Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential

8. Eli Lilly and Company (NYSE:LLY)

Upside Potential: 24.73%

Number of Hedge Fund Holders: 115

Eli Lilly and Company (NYSE:LLY), founded in 1876 and based in Indianapolis, Indiana, is a global pharmaceutical industry leader. The company creates novel drugs for diabetes, obesity, oncology, immunology, and the brain. It promotes well-known treatments such as Mounjaro, Trulicity, Zepbound, Verzenio, and Jaypirca.

Eli Lilly and Company (NYSE:LLY) surpassed expectations in 2024, exceeding initial sales guidance by $4 billion and EPS estimates by $4 per share, even after accounting for IPR&D expenditures. This result was driven by significant momentum in the incretin market, where Mounjaro and Zepbound continued to grow their presence.

Looking ahead, the year 2025 is predicted to be significant. The Phase 3 ACHIEVE-1 trial, which is investigating Orforglipron in type 2 diabetes, is expected to report results in Q2. It recently stated that the oral medication resulted in an 8% weight loss over 40 weeks, outperforming Ozempic’s 6% in similar individuals, and decreased blood sugar by 1.3%. Despite being slightly lower than Ozempic’s 2.1% reduction, Orforglipron’s oral convenience may provide a competitive advantage in a market that is traditionally dominated by injectables. The company’s share price increased by 16% upon the announcement of the results.

Furthermore, in Q3, Eli Lilly and Company (NYSE:LLY) anticipates critical results from the ATTAIN-1 and ATTAIN-2 obesity trials, which will support regulatory applications for Orforglipron in obesity by late 2025. Additional catalysts include SURPASS-CVOT data for tirzepatide in cardiovascular outcomes and preliminary results for Retatrutide from the TRIUMPH-4 study in overweight patients with osteoarthritis.

Eli Lilly and Company (NYSE:LLY) is also expanding its cancer pipeline through Jaypirca trials, which are aiming at earlier-stage medicines, and through neurodegenerative research. These accomplishments highlight the pharmaceutical company’s strong innovation engine, making it a strong pick in Ken Fisher’s stock portfolio.